- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Tweed Renews License to Produce and Sell Marijuana Under MMPR
Tweed Inc, a wholly owned subsidiary of Canopy Growth Corp. (TSXV:CGC), announced that it has renewed its license to produce and sell marijuana under Health Canada’s Marihuana for Medical Purposes Regulations (MMPR).
Tweed Inc, a wholly owned subsidiary of Canopy Growth Corp. (TSXV:CGC), announced that it has renewed its license to produce and sell marijuana under Health Canada’s Marihuana for Medical Purposes Regulations (MMPR).
As quoted in the press release:
The renewed license, which is valid for 14 months until January 19, 2017, allows Tweed to produce and sell up to 3,500 kg of dried marijuana. In addition, Health Canada has renewed Tweed’s supplemental license to produce fresh marijuana and/or cannabis oil, over the same period.
Bruce Linton, chairman and CEO of Canopy Growth, commented:
This is an indication that Health Canada has confidence in Tweed’s ability to continue to meet the rigorous production, product quality, and security requirements of the regulatory regime. Producing cannabis of this level of quality on a large scale, ensuring it is delivered strictly to the designated registered patient, and ensuring the customer care experience is consistently exceptional, requires a high degree of expertise across multiple functional areas. Tweed continues to prove that we are unsurpassed in these capabilities.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.